Podcasts about Edwards Lifesciences

This is Derek Miller, Speaking on Business. Utah's life sciences industry is a key driver of our state's economy, and BioUtah serves as its dedicated trade association — working to ensure the state remains a leader in life sciences innovation. President and CEO, Kelvyn Cullimore, joins us with more. Kelvyn Cullimore: As one of the fastest-growing biotech hubs in the nation, Utah's life sciences industry generates over 22 billion dollars in GDP, 182,000 jobs and wages at nearly 50 percent higher than the state average. This industry is comprised of medical device and diagnostic manufacturers, pharmaceutical companies, medical labs, and research facilities, whose products touch millions of patients each year and help fuel the Utah economy. BioUtah members include medical device manufacturers like Merit Medical, BD, Stryker and Fresenius; medical laboratories like ARUP and Nelson Labs; and pharmaceutical developers Teva, Denali, and Halia Therapeutics, among many others. Utah punches well above its weight in bringing innovative medical technologies to patients worldwide, such as brain and computer interface technology from Blackrock Neurotech, innovative heart valve replacement systems by Edwards Lifesciences, AI for enhanced drug discovery by Recursion, and Nusano's radioisotope technology, and so much more. Derek Miller: BioUtah is on a mission to build awareness and advance Utah's innovative, patient-focused life sciences industry. Through their work, they're making a real difference in the lives of Utahns. Learn more at BioUtah.org today. I'm Derek Miller, with the Salt Lake Chamber, Speaking on Business. Originally aired: 5/13/25

Odhadem 11 % české populace splňuje diagnostická kritéria závislosti na alkoholu. Dostupnost alkoholických nápojů je v Česku velmi vysoká.

Renee Bernard, Director of the Cardiovascular Institute at Brown University Health - Rhode Island Hospital, joins Becker's to discuss overcoming access and throughput challenges, leveraging data for resource management, and preparing for the future of structural heart interventions.This episode is sponsored by Edwards Lifesciences.

In this episode of the Global Medical Device Podcast, host Etienne Nichols sits down with Scott Pantel, CEO and founder of Life Science Intelligence (LSI), to explore how LSI bridges the gap between medtech innovation and commercialization. Scott shares LSI's origin story, the evolution of its events, and the importance of cultivating meaningful relationships within the medtech ecosystem. Learn how LSI's global meetings—from Dana Point to Portugal, London, and Singapore—create spaces where deals happen, ideas flourish, and the future of patient care is shaped. Plus, Scott offers actionable advice for medtech founders preparing for investor pitches and shares inspiring stories of industry impact.Key Timestamps[02:10] – LSI's partnership with Greenlight Guru and the value of ecosystem collaboration[05:30] – Scott Pantel's journey into medtech and how LSI was born[12:20] – Reinventing the investor meeting experience: “There's got to be a better way”[18:45] – The power of unexpected connections: Coffee chats, cab rides, and transformative deals[25:10] – Heartfelt story: How an Edwards Lifesciences valve saved Scott's aunt's life[31:00] – The role of fun and social events in serious deal-making (yes, golf included!)[39:20] – Global expansion: Why LSI is heading to Singapore in 2025[45:50] – What makes a medtech pitch stand out to investors[53:15] – The importance of patient-centered innovation and next-gen leadership[59:00] –

Bruce Koplan, MD, FHRS, Brigham and Women's Hospital is joined by Erik Andrews, MD, MPH, Brigham and Women's Hospital, and Matthew Reynolds, MD, MS, FHRS, Lahey Hospital & Medical Center to discuss why Oral anticoagulation is recommended after ablation for atrial fibrillation among patients at high risk for stroke. Left atrial appendage closure is a mechanical alternative to anticoagulation, but data regarding its use after atrial fibrillation ablation are lacking.  https://www.hrsonline.org/education/TheLead https://www.nejm.org/doi/full/10.1056/NEJMoa2408308 Host Disclosure(s): B. Koplan: Honoraria/Speaking/Consulting: GE Healthcare    Contributor Disclosure(s): E.  Andrews: Stocks, Publicly Traded: Apple, Inc. Microsoft, Intel, Inc., Moderna Therapeutics, Fellowship Support: Boston Scientific, Medtronic, Inc. M. Reynolds: Honoraria/Speaking/Consulting: Medtronic, Edwards Lifesciences, Philips, iRhythm Technologies, Membership on Advisory Committees: Affera, Inc.   This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365 https://www.heartrhythm365.org/URL/TheLeadEpisode91

This medical and educational podcast was supported by Edwards Lifesciences and is intended for healthcare professionals. In this final episode, we learn about how Interventional Cardiologist can play a key role in improving the referral pathway of TAVI patients Moderator Jonathan Sackier - EMJ Speakers:   Derk Frank – Interventional Cardiologist, Professor of internal medicine, critical care, and cardiology and Director of the Department for Internal Medicine III (Cardiology, Angiology and Intensive Care Medicine,) at the University Hospital Schleswig-Holstein in Kiel, Germany and the German Centre for Cardiovascular Research   Sagar Doshi – Consultant Interventional Cardiologist and Director of the Transcatheter Aortic Valve Implantation (TAVI) programme at the Queen Elizabeth Hospital Birmingham. and Professor of Cardiology Honorary Associate Clinical Professor at the University of Birmingham, and an Honorary Professor at University College Birmingham, in the UK.

On this episode of the Spot Radio Podcast, host Charlie Webb CPPL sits down with Elon Goldbaum from the Network Partner Group to delve into the intricacies of performing a Corrective and Preventive Action (CAPA). They discuss the framework that underpins the CAPA process, highlighting its crucial role in ensuring product quality and compliance in the medical device industry.Charlie and Elon explore the vital importance of the CAPA process, shedding light on how it helps organizations identify, address, and prevent potential issues. They also share valuable tips and strategies to make the CAPA process more manageable and effective, ensuring that businesses can maintain high standards of safety and quality.Tune in to gain insights from industry experts and learn practical advice that can be applied to your own CAPA initiatives. This episode is a must-listen for anyone involved in quality assurance, regulatory affairs, or medical device manufacturing.About our guest:As Vice President, Client Solutions for Network Partners Group, Elon (Lon) brings over 20 years of experience in the medical device field specializing in packaging, labeling, quality management systems, CAPA and sterilization. Lon's multifaceted background provides support and leadership to Network Partners' packaging consulting, quality assurance, labeling, and the Apprentice Leadership Program.Prior to joining Network Partners, Lon held various roles with Baxter Healthcare, Edwards Lifesciences, Endologix and Danaher with a wide range of responsibilities. Lon earned his Bachelor of Science degree in Packaging from Michigan State University.Elon Goldbaum e-mail: elon.goldbaum@onenpg.com

In this episode of the MedTech Talent Lab podcast, host Mitch Robbins interviews Garrett Johnson, the new CEO of Quantus Cardiovascular. Garrett shares his journey from a mechanical tinkerer in his youth to a leader in the medical device industry, having had experiences leading R&D programs for companies like Edwards Lifesciences, Foldax and inQB8 Medical Technologies. He discusses his early influences, the transition from medicine to medical devices, and the importance of hands-on experience in R&D. Garrett reflects on his leadership evolution, the challenges of building a strong team, and the risks associated with career growth. He also shares insights on balancing work and family life, the exciting developments at Quantus, and the value of mentorship and continuous learning.Tune in for all of Garrett's nuggets of wisdom!Garrett Johnson on LinkedIn:https://www.linkedin.com/in/garrett-johnson-medtech/Quants Cardiosvascular on the web:https://www.quantuscardio.org/home

In this episode of Structural Heart Talks, Todd Brinton, MD, Chief Scientific Officer & CVP, Advanced Technology at Edwards Lifesciences, discusses Edwards' vision of future innovative technologies that elevate patient care and expand the possibilities of structural heart therapies. Brinton reflects on his journey from biomedical engineering to pioneering roles in MedTech, including his work at Shockwave Medical, and shares how these experiences shaped his mission to create impactful technologies for patients worldwide. The conversation dives deep into Edwards' evolving focus on structural heart failure and non-valvular structural heart therapies, emphasizing investigational programs that challenge traditional approaches and push the boundaries of interventional cardiology. Brinton highlights how Edwards fosters a mission-driven culture of collaboration, uniting engineering, clinical expertise, and market insights to tackle some of the most complex challenges in cardiac care. The episode also underscores the transformative role of mentorship in Brinton's career and his commitment to paying it forward by empowering others in the MedTech space. Drawing on personal stories, Brinton illustrates how embracing failure and leveraging diverse perspectives have driven innovation at Edwards, paving the way for new therapies that can improve care for patients globally. * Please note that this episode was recorded before the sale of Edwards' Critical Care business unit to BD, which closed on Sept 3, 2024. Thank you to Integer for sponsoring this episode of Structural Heart Talks. To learn more about how Integer supports medical device companies, visit www.Integer.net. Thank you for listening to the Structural Heart Talks podcast. Tune in and subscribe to the DeviceTalks Podcast Network wherever you get your podcasts and follow youtube.com/@DeviceTalks or the Structural Heart Talks on YouTube Podcasts to ensure you never miss an episode.

In this episode of Structural Heart Talks, Larry Wood, Corporate VP and Group President, Transcatheter Aortic Valve Replacement and Surgical Structural Heart at Edwards Lifesciences, discusses the transformative journey of transcatheter aortic valve replacement (TAVR) and the SAPIEN valve. Wood reflects on the innovation that enables minimally invasive heart valve replacement, which has become the standard of care for severe aortic stenosis and offers patients faster recovery and greater independence. The conversation explores Edwards' efforts to expand access to TAVR, emphasizing the importance of reducing undertreatment and addressing outdated clinical guidelines that delay intervention. Wood also highlights findings from the recent early TAVR study, which challenges long-standing paradigms and advocates for changes to the guidelines to allow earlier treatment of aortic stenosis before symptoms appear. Thank you to Confluent Medical Technologies for sponsoring this episode of Structural Heart Talks. To learn more about how Confluent Medical supports medical device companies, visit: www.confluentmedical.com. Thank you for listening to the Structural Heart Talks podcast. Tune in and subscribe to the DeviceTalks Podcast Network wherever you get your podcasts and follow youtube.com/@DeviceTalks or the Structural Heart Talks on YouTube Podcasts to ensure you never miss an episode.

Send us a textGeoff Gaw is an experienced mechanical engineer specializing in the medical device industry. With a degree in Mechanical Engineering and minors in Materials Science and Energy Engineering from Cal Poly Pomona, he has held leadership roles at Edwards Lifesciences, Medtronic, and Applied Medical. His expertise spans project management, product and process development, and manufacturing support. He has overseen the development of complex medical devices, scaling teams, and driving operational excellence from early development stages to mass production. Currently, he serves as a Sr. Principal Engineer at Edwards Lifesciences.Aaron Moncur, hostAbout Being An Engineer The Being An Engineer podcast is a repository for industry knowledge and a tool through which engineers learn about and connect with relevant companies, technologies, people resources, and opportunities. We feature successful mechanical engineers and interview engineers who are passionate about their work and who made a great impact on the engineering community. The Being An Engineer podcast is brought to you by Pipeline Design & Engineering. Pipeline partners with medical & other device engineering teams who need turnkey equipment such as cycle test machines, custom test fixtures, automation equipment, assembly jigs, inspection stations and more. You can find us on the web at www.teampipeline.us

This week, Chitrang Dave, Global Head of Enterprise Data & Analytics at Edwards Lifesciences, joins us to discuss the transformative power of real-time data, AI, and collaboration in medical device manufacturing and support.  He and host, Ross Katz, dive into how real-time data from IoT devices is reshaping quality assurance in medtech and what the future holds for medtech as big tech players like Apple and Meta enter the healthcare arena.  Together, they discuss everything from AI-powered patient identification to the integration of consumer wearables with FDA-approved medical devices. Tune in to hear how collaboration, innovation, and cutting-edge technology are improving patient outcomes and revolutionizing healthcare. Data in Biotech is a fortnightly podcast exploring how companies leverage data innovation in the life sciences. Chapter Markers [01:36] Chitrang shares the experience that led him to work at leading data and analytics organizations and what work there is to be done [04:09] Chitrang highlights the role of IoT devices in medical device manufacturing, where real-time data can drive automation and improve quality assurance [06:25] What is driving innovation right now in research and development, and how companies like Apple are disrupting the medical device space  [09:23] Chitrang talks about how connectivity in devices and the expectation of the user to be able to use an intuitive interface are evolving into more real-time medical device technology  [11:47] The importance of keeping patient data private between the patient and the practitioner while using anonymized data to create solutions and identify patterns in health  [13:25] Using data to create a complete picture of the patient in order to make their life easier  [14:20] Chitrang discusses the challenge of manufacturing medical devices when there are issues with raw materials  [16:30] Chitrang discusses the potential for automation for real-time data in manufacturing [19:17] Ross and Chitrang discuss the value of having comprehensive data to personalize treatments and ensure timely responses, especially for scenarios where early detection of Alzheimer's can save trillions of dollars [21:27] Chitrang mentions significant collaborations, such as the Cancer AI Alliance, where tech giants like AWS, Microsoft, NVIDIA, and Deloitte are working together to address critical problems in healthcare [27:10] How real-time data from medical devices could improve patient outcomes, stakeholder coordination and future trends  [28:29] Closing thoughts and where to find Chitrang Dave online  Download CorrDyn's latest white paper on “Using Machine Learning to Implement Mid-Manufacture Quality Control in the Biotech Sector.” Find the white paper online at: https://connect.corrdyn.com/biotech-ml

Edwards Lifesciences Corporation v. Cardiovalve Ltd.

In this episode of Structural Heart Talks, Wayne Markowitz, General Manager and SVP, Surgical Structural Heart at Edwards Lifesciences, discussed the evolving landscape of the structural heart space, emphasizing the renewed focus at Edwards under new leadership. Markowitz highlights the importance of the surgical structural heart business, with a strong emphasis on innovation and collaboration with cardiac surgeons. He emphasizes Edwards' 65-year legacy in innovation driven by partnerships with the surgical community, focusing on addressing unmet patient needs. The conversation also touched on the RESILIA portfolio, featuring surgical valves and conduits, and highlights ongoing clinical trials with positive data outcomes. Looking ahead, Markowitz shares his optimism about the future of the surgical structural heart business, emphasizing the need to bring more patients into the treatment system and the potential for growth in emerging markets. Thank you to Resonetics for sponsoring this episode of Structural Heart Talks. To learn more about how Resonetics supports medical device companies, visit: https://shorturl.at/E1wO8 Thank you for listening to the Structural Heart Talks podcast. Tune in and subscribe to the DeviceTalks Podcast Network wherever you get your podcasts and follow youtube.com/@DeviceTalks or the Structural Heart Talks on YouTube Podcasts to ensure you never miss an episode.

Shannon Chamber has launched the programme for the second annual 'Sustainability Week, which will be held in Shannon from Wednesday, 25 September to Wednesday, 2 October. The 'Week', which features ten events and a day-long conference, is being delivered by Shannon Chamber via its member-led Mid-West Sustainability Network. It is sponsored by ESB and supported by companies including, Eli Lilly, Ei Electronics, EY, Climeaction, Element Six, Astatine, AIB, Shannon Chamber Skillnet, GreenTech Skillnet, Antaris Consulting, Mavarick, Vitalograph, Fine Grain Property and Aerogen. A unique addition to the Sustainability Week 2024 programme will be the placement, by ESB, of their new Hydrogen Power Unit at the Shannon Airport Business Park to highlight the versatility of hydrogen fuel cell technology in different applications. The demonstration will be in place for the full week and will be open for guided tours on Monday, 30 September and Tuesday, 1 October from 10am to 4pm.Advance booking is required, and visits will be accommodated in groups of six. Bookings can be made at https://www.snnairportgroup.ie/sustainability/esb-hydrogen-fuel-cell-tour/. The expansive Sustainability Week programme comprises a mix of daily in-person and online events, each addressing four key sustainability areas - Waste, Water, Energy, Biodiversity. Companies presenting during the 'Week' include: ESB Generation and Trading, ESB Smart Energy Services, Aerogen, Chemifloc Group, Ei Electronics, Uisce Éireann, Wyeth Nutrition, Southern Region Waste Planning Office, SEAI, Clean Ireland Recycling, Vitalograph, The Shannon Airport Group, Antaris Consulting, All-Ireland Pollinator Plan, Veon Forestry and Ecology, and The Change We Need. The one-day conference (The S4 Conference), which will be held in Westpark Innovation Campus in Shannon, will bring the 'Week' to a close on Wednesday, 2 October. Companies presenting at the conference include ESB Generation and Trading, The Shannon Airport Group, Lilly Limerick, Element Six, Edwards Lifesciences, Heraeus Precious Metals Ltd. The day will conclude with a panel discussion, led by conference MC, Barry Gavin, and involving ESB Moneypoint, Shannon Foynes Port Company, SEAI and Clare County Council. A 'Street Event' included in the conference programme will include information boards produced by companies focusing in on specific projects they have undertaken, the results attained and how the project contributed to the company's net zero goals. Companies wishing to feature in this 'Street Event' should contact Shannon Chamber at admin@shannonchamber.ie. The conference venue will also include an 'Exhibitor Section', where attendees can meet companies and organisations whose services can be deployed to commence or enhance sustainability undertakings. Launching Sustainability Week and the S4 Conference, Shannon Chamber chief executive, Helen Downes said: "The objective of Sustainability Week is to place sustainability centre-stage in companies' minds through showcasing the types of projects companies are undertaking to reduce their carbon footprint. It follows the very successful inaugural 'Week' we hosted in 2023. We are looking forward to hearing from a different cohort of companies this year, each of whom have embedded sustainability into the products and processes. "We are delighted that ESB, in conjunction with The Shannon Airport Group, has chosen to place its new hydrogen power generation demonstration unit in Shannon during the week. The unit, produced by GeoPura, a UK-based renewable energy company, and their partner, Siemens Energy, is truly innovative. Having it in Shannon for a week will really enhance what the Mid-West Sustainability Network is seeking to achieve - helping companies to attain net zero. Fuel cell technology, which converts hydrogen to electricity will play a leading role in this transition. To show how this can be achieved, particularly as part of Sustainability Week is a progressive step fo...

In this episode of DeviceTalks Weekly podcast, Host Tom Salemi introduces one DeviceTalks West speaker. Ray Baker, MD, vice president and chief medical officer, neuromodulation at Boston Scientific, introduces DeviceTalks Weekly listeners to Intracept, a procedure approved by the FDA to treat forms of back pain. Dr. Baker will be a speaker at DeviceTalks West on Oct. 17 where the clinical and commercial details will be discussed. Register now at West.Devicetalks.com. Use the code mentioned in the podcast to save 25% off the price of registration. Salemi also invites listeners to attend the Connected Health Series taking place Sept. 10-12. Sponsored by Maxon and S3 Connected Health, virtual attendees can hear from Adona Medical, Baxter, BD and Canary Medical about the future of sensors and other connected technologies. MassDevice Editor Chris Newmarker brings another batch of Newmarker's Newsmakers including Novocure, Medtronic, Johnson & Johnson MedTech, Edwards Lifesciences and the Big 100. Thanks for listening to the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network so you don't miss a future episode.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Steward Health is closing two Ohio hospitals and a Pennsylvania facility due to financial reasons, drawing criticism from healthcare workers and unions. McLaren Health Care in Michigan is facing disruptions from a ransomware attack, while Humana has settled whistleblower allegations of Medicare Part D fraud for $90 million. A judge has struck down an FTC ban on noncompete agreements nationwide, impacting the healthcare industry. Massachusetts has brokered agreements for Steward to sell five hospitals as part of bankruptcy proceedings. The healthcare industry is focusing on delivering patient-centric experiences and combating burnout. Recent articles cover topics such as medical tourism, health care fights, private equity deals, and reproductive freedom. As Bristol Myers' schizophrenia drug nears approval, AbbVie and other competitors are looking to enter the market with new antipsychotics to improve patient adherence. BridgeBio is sending rare disease drugs to a new company called GondolaBio, backed by $300 million from investors. Regeneron faces FDA delays for a myeloma drug due to manufacturing issues. Biomarin has reshuffled its executive team with new heads of R&D and business development. Lilly's tirzepatide has shown promising results in reducing the risk of type 2 diabetes progression. Drugmakers are strategizing for upcoming patent expirations by finding new products and markets. Edwards Lifesciences is continuing its mergers and acquisitions spree by acquiring Genesis MedTech's TAVR technology and investing $25 million in the company. In other news, Johnson & Johnson is buying heart failure implant maker V-Wave for up to $1.7 billion, while Medtronic asserts that its diabetes strategy remains unchanged despite a partnership with Abbott. The FDA defends Jeff Shuren's tenure amid ethics concerns, Dupont acquires Donatelle Plastics for $313 million, and a survey reveals that small biopharma and CROs are increasingly using multiple trial technologies. Steward Hospitals is closing two facilities in Ohio and one in Pennsylvania due to financial reasons. Dissatisfaction with electronic health records (EHR) is increasing nurses' burnout risk, with a third of nurses attributing their burnout symptoms to EHR issues. Updated COVID-19 vaccines from Pfizer and Moderna have been approved by the FDA to better match current virus strains. The Center for Medicare & Medicaid Services (CMS) has received 12,000 complaints of noncompliance with surprise billing regulations and has won $1.7 million in restitution.The ongoing struggle for health equity in the pharmaceutical industry highlights disparities in cancer treatment access and outcomes. Efforts to improve outcomes for black cancer patients through increased screening rates have not been successful, with income disparity playing a significant role in cancer rates among different backgrounds. Various industry leaders and experts share insights on strategies to improve diversity in clinical trials, tackle health disparities, and promote health equity.This week in gene therapy news, Biomarin has reshuffled its C-suite with new executives from Amgen and Roche, while Avidity and Kymera have raised fresh funds. Zealand and Arrowhead are advancing obesity drugs, while Bluebird has narrowed its launch guidance. The rise of antibody-drug conjugates in cancer treatments is discussed along with upcoming events in the biopharma industry.For more updates on gene therapy, subscribe to Biopharma Dive's newsletter.

In this episode of the DeviceTalks Weekly Podcast, Host Tom Salemi talks with Tasneem Dohadwala, founding partner at Excelestar Ventures about how the small firm employs analytics, know-how, and a belief that companies are best led by diverse management teams. MassDevice Editor Chris Newmarker returns with his Newmarker's Newsmakers including outgoing FDA CDRH Leader Jeff Shuren, the New York Times, Medtronic, Zoll Medical, Vyaire Medical, Johnson & Johnson MedTech, V-Wave, and Edwards Lifesciences. This episode is sponsored by DeviceTalks West. Listen to the podcast to hear the discount code that will save you 25% of the price of registration. Go to West.DeviceTalks.com. We'll also hear a message from regulatory firm MedTech Impact Partners. Thank you for listening to the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network.

In the inaugural episode of our newest podcast, Structural Heart Talks, we sit down with Daveen Chopra, Corporate VP and GM of Transcatheter Mitral and Tricuspid Therapies (TMTT) at Edwards Lifesciences. In the episode, Chopra discusses the unique challenges of advancing therapies for the mitral and tricuspid valves, which have historically been more difficult to treat than the aortic valve due to their complex and varied nature. He details Edwards Lifesciences' efforts to innovate in this space with technologies like the PASCAL valve repair system and the EVOQUE tricuspid valve replacement system, the first transcatheter tricuspid valve replacement approved in both the US and Europe. Later, Chopra explains the importance of a focused approach at Edwards Lifesciences, where the company's specialization in structural heart disease enables deeper knowledge and more targeted innovation. The conversation also explores the intricate process of planning and executing these advanced procedures, which require close collaboration between interventional cardiologists and echocardiographers. Chopra underscores the ongoing commitment to clinical evidence and real-world outcomes as key drivers of future success in this rapidly evolving field. Looking ahead, he emphasizes the need to increase awareness, diagnosis, and treatment rates for valve diseases, noting that many patients still go untreated due to a lack of awareness. Thank you to Resonetics for sponsoring this episode of Structural Heart Talks. To learn more about how Resonetics supports medical device companies, visit: https://shorturl.at/E1wO8 Thank you for listening to the Structural Heart Talks podcast. Tune in and subscribe to the DeviceTalks Podcast Network wherever you get your podcasts and follow youtube.com/@DeviceTalks or the Structural Heart Talks on YouTube Podcasts to ensure you never miss an episode.

Discover the evolving healthcare landscape as Sandie Dela Cruz shares her journey from audiology to spearheading digital solutions in the medical device industry.  In this episode, Sandie discusses how her early experiences in audiology and operational excellence laid the groundwork for her medical device industry role. She delves into the transformative potential of AI in medicine, from virtual reality simulations for physician training to advanced diagnostic tools. Sandie also explores the challenges and opportunities in integrating AI into healthcare, highlighting its impact on efficiency, patient care, and regulatory hurdles. Whether you're a healthcare professional, tech enthusiast, or curious about the future of medicine, this conversation offers valuable insights into the innovations shaping the future of healthcare. Resources: Connect with and follow Sandie Dela Cruz on LinkedIn. Learn more about Edwards Lifesciences on their LinkedIn and website. Listen to Siemens Healthineers' podcast, Healthcare Perspectives, here.

In this episode of the DeviceTalks Weekly, Chris Landon returns to the podcast but this time as CEO of Natus Neuro, a company building out a monitoring, diagnostics and data collection platform to help diagnose and treat neurological disorders. This episode is sponsored by DeviceTalks West. Host Tom Salemi and Chris Newmarker, editor of MassDevice, review this week's Newmaker's Newsmakers - aka the week's biggest medtech stories. Top newsmakers include Imperative Care, the FDA, neuro start-Ups, Inspire Medical and Edwards Lifesciences. Thanks for listening to this episode of the DeviceTalks Weekly Podcast. Subscribe now to the DeviceTalks Podcast Network.

US futures are pointing to a lower open today. European equity markets have opened in the negative territory, following weaker levels in Asian markets. Nasdaq experienced largest one-day drop since December 2022. Sell-off is attributed to disappointing tech earnings takeaways. Yen continues to strengthen ahead of next week's BOJ meeting, rallying to its highest against US dollar since early May. Pick-up in Fed rate cut expectations also comes as the BOJ nears decision to hike again.Companies Mentioned: Disney, Amazon, Comcast, Warner Bros. Discovery, Edwards Lifesciences

William H. Sauer, MD, FHRS, CCDS, Brigham and Women's Hospital is joined by Andrés Felipe Miranda-Arboleda, MD, Brigham and Women's Hospital Babak Nazer, MD, University of Washington to discuss how Purkinje fibers play an important role in the initiation and maintenance of ventricular fibrillation (VF) and polymorphic ventricular tachycardia (PMVT). Fascicular substrate modification (FSM) approaches have been suggested to treat recurrent VF in case reports and small case series. https://www.hrsonline.org/education/TheLead https://www.jacc.org/doi/10.1016/j.jacep.2024.03.035 Host Disclosure(s): W. Sauer: Honoraria/Speaking/Consulting: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific, Research: Medtronic   Contributor Disclosure(s): A. Miranda-Arboleda: Nothing to disclose. B. Nazar: Honoraria/Speaking/Consulting: Biosense Webster, Boston Scientific, Edwards Lifesciences, Research: Biosense Webster

Fri, 07 Jun 2024 10:00:00 +0000 https://podcast8f7bd0.podigee.io/278-new-episode 17ab5a1f15c5bdb1bcce8610a1929374 Herzlich willkommen zu Folge 243 unseres Aktienpodcasts mit Marcel und Philipp von Modern Value Investing! In dieser Episode tauchen wir tief in die Welt der Small Caps ein und entdecken spannende Schnäppchen. Themen der Woche: Crowdstrike & Cloudflare: Wir analysieren die beeindruckenden Zahlen von Crowdstrike und diskutieren die Übernahme von BastionZero durch Cloudflare. Erfahrt mehr über die strategische Partnerschaft und die innovativen Zero Trust-Schutzmaßnahmen. Viessmann und Encavis: Der US-Finanzinvestor KKR und die Familie Viessmann haben 68,55% der Anteile an Encavis übernommen. Wir beleuchten die Hintergründe und die Pläne der Viessmann-Familie, in die Energiewende zu investieren. KI im Fokus: Auf der Computex-Messe stellen AMD und Nvidia ihre neuesten KI-Chips vor. Wir diskutieren, wie diese Innovationen die Zukunft der Technologie beeinflussen werden. Umsatzkiller Wegovy, Ozempic & Co.: Neue Studien zeigen, dass Medikamente wie Wegovy und Ozempic den Umsatz der Pharmaindustrie drastisch senken könnten. Wir werfen einen Blick auf die potenziellen Auswirkungen. Edwards Lifesciences & Becton Dickinson: Becton Dickinson plant, für 4,2 Mrd. USD einen Teil von Edwards Lifesciences zu übernehmen. Wir analysieren die Details des Deals und die erwarteten positiven Effekte. FTI-Insolvenz: Der Reisekonzern FTI muss Insolvenz anmelden. Wir diskutieren die Gründe und die Konsequenzen dieser Entwicklung. Top & Flop der Woche: Top: Die Europawahl und der Verkauf von Deutsche Telekom Aktien durch den Bund. Flop: Gamestop und das Desaster um New Work (XING). Investmentidee der Woche: Wir stellen euch Alexandria Real Estate und Bristol Myer Squibb als interessante Investmentmöglichkeiten vor. Hört rein, um alle Details zu erfahren und bleibt informiert über die aktuellen Entwicklungen am Aktienmarkt! Verpasst keine Folge und abonniert unseren Podcast!

Plus: Jury selection begins in Hunter Biden's criminal trial. Medical technology company Becton Dickinson agreed to acquire a unit of Edwards Lifesciences for $4.2 billion. J.R. Whalen reports. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

This piece focuses upon the Hypotension Predictive Index (HPI) technology. We look at the validation process of HPI, addressing criticisms and clarifying its predictive ability for hemodynamic instability. How important is it to understand the underlying causes of instability rather than solely relying on blood pressure readings? What is the role of HPI in early detection and proactive management? The discussion also touches on the limitations of traditional mean arterial pressure (MAP) monitoring and the need for a holistic approach to hemodynamic assessment. Presented by Desiree Chappell, TopMedTalk's co-editor in Chief, speaking with Monty Mythen, Senior Vice President Medical Affairs, Edwards Lifesciences, Critical Care, Emeritus Professor of Anaesthesia and Critical Care, University College London, Thomas Sheeran, Senior Director Medical Affairs, Edwards Lifesciences, and Simon Davies, Consultant Anaesthetist at York Teaching Hospital NHS Foundation Trust. The paper 'Comparison of Differences in Cohort (Forward) and Case Control (Backward) Methodological Approaches for Validation of the Hypotension Prediction Index' is here: https://pubs.asahq.org/anesthesiology/article/doi/10.1097/ALN.0000000000004989/139987/Comparison-of-Differences-in-Cohort-Forward-and?searchresult=1 Here's the link to the Physiology Lab section of last year's ASA symposium on YouTube: https://youtu.be/yfl1VMMgIRs?si=YxGfOs-pdlIVVGt1 Here are publications relating HPI to hemodynamic instability at a microcirculation level: https://pubmed.ncbi.nlm.nih.gov/33755645/ https://pubmed.ncbi.nlm.nih.gov/36335548/

This piece is part of our coverage of The International Anesthesia Research Society (IARS) annual meeting. This wide ranging conversation tackles hemodynamics, intraoperative hypotension and its implications. We also discuss finance for medical practitioners and patient-centered research. Presented by Desiree Chappell, Vice President of Clinical Quality at NorthStar Anesthesia and TopMedTalk co-editor in Chief and Monty Mythen, TopMedTalk's founder and Senior Vice President Medical Affairs, Edwards Lifesciences with their guest Wael Saasouh, Anesthesiologist and Director of Research for NorthStar Anesthesia.

Bruce A. Koplan, MD, MPH, FHRS, Brigham Women's Hospital is joined by Matthew R. Reynolds, MD, MS, FHRS, Lahey Hospital & Medical Center, and Esseim Sharma, MD, University Hospitals Cleveland to discuss integrating patient-specific cardiac implantable electronic device (CIED)-detected atrial fibrillation (AF) burden with measures of health care cost and utilization allows for an accurate assessment of the AF-related impact on health care use.  https://www.hrsonline.org/education/TheLead https://www.jacc.org/doi/full/10.1016/j.jacep.2023.12.011 Host Disclosure(s): B. Koplan: Speaking/Consulting Honoraria: GE Healthcare Contributor Disclosure(s): M. Reynolds: Speaking, Teaching, and Consulting: Medtronic, Edwards Lifesciences, Philips, iRhythm Technologies, Membership on Advisory Committees: Affera, Inc. E. Sharma: Nothing to disclose. This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365     https://www.heartrhythm365.org/URL/TheLeadEpisode61

In the final episode of MedtechWOMEN Talks season one, we are joined by YJ Oh, SVP US Sales, Marketing and Commercial Operations at Edwards Lifesciences, who takes us through the intricate process of medical device commercialization. Starting with her unique entry into the medtech industry, YJ shares her comprehensive journey from sales to global marketing, emphasizing the significant role of upstream marketing in shaping product development and downstream efforts in executing commercial strategies. In the discussion, YJ highlights the criticality of understanding market needs right from the inception of a product idea, ensuring that every development phase aligns with customer insights and real-world applicability. She provides a glimpse into the key collaborations across various departments and touches on the essential feedback mechanisms in place, ensuring devices meet the stringent requirements and expectations set forth by both regulatory bodies and the end-users, primarily physicians. Her insights extend into the strategic considerations for global market penetration, discussing how different regulatory landscapes affect the accessibility and success of medical devices across borders. TL;DR – Key Takeaways: - The integration of market insights from the beginning is crucial for successful medical device commercialization. - Collaborative efforts across various functions are vital to address the comprehensive demands of product development. - Strategic global considerations are imperative to navigate varying regulatory and market conditions effectively. Thank you to our season one sponsors Aptyx, Catalyze Healthcare, Confluent Medical Technologies, and Cretex Medical! https://aptyx.com/ https://catalyzehealthcare.com/ https://confluentmedical.com/ https://www.cretex.com/ Tune in and subscribe to DeviceTalks on all major podcast channels and follow youtube.com/@DeviceTalks to ensure you never miss an episode. Thank you for listening to MedtechWOMEN Talks!

Bryan Ramirez with Edwards Lifesciences spoke with “Problem Solved” during the Applied Ergonomics Conference 2024, which took place March 25-28 in Louisville, Kentucky.

Our coverage of the 18th World Congress of Anaesthesiologists (WCA 2024) continues. In this piece we cover assisted fluid management in anesthesia. Using AI in anesthesia and its potential impact on anesthesiologists. The validity of the hypotension prediction index in academic debate. Reducing hypertension in surgical patients using HPI. Desiree Chappell and Monty Mythen speak with Thomas Scheeren, Senior Director Medical Affairs, Edwards Lifesciences and Paul Van Beest, Anaesthesiologist, Medical Center Leeuwarden, University Medical Center Groningen.

Cardiovalve Ltd. v. Edwards Lifesciences Corporation

Hoy en el consultorio de Bolsa de Capital Intereconomía, el analista independiente Miguel Méndez ha analizado la situación actual de las principales bolsas mundiales. El experto cree que las bolsas, especialmente las americanas, pueden empezar a perder fuerza y comenzar a bajar. "Tengo la duda de si el S&P500 va a poder romper los 5.100 puntos o eso va a ser el punto de inflexión para que las Bolsas se vayan hacia abajo". Por otro lado el analista ha destacado la importancia de la agenda económica de los próximos días, "los datos de PIB e IPC que se van a publicar en EEUU van a ser muy importantes". Y también avisa a los oyentes, "vamos a ver si se produce la rotación de valores más conservadores a algo más de riesgo o no". En cuanto al principal indicador de la bolsa española, Ibex 35, el experto considera que "no lo está haciendo mal". Y cree que la segunda resistencia la tiene en 10.300. Además Méndez ha destacado la debilidad de la 'utilities' y piensa que hasta que no se vislumbre la bajada de tipos van a sufrir. Aunque creen que van a tener una oportunidad en la segunda parte del año. Miguel Méndez no solo ha realizado un análisis de los principales mercados a nivel mundial. También ha respondido a las consultas de los oyentes, donde los valores destacados fueron: Indra, Edwards Lifesciences, ASML Holding, Logista, Tesla, BASF, Mercedes Benz y Ferrari.

This piece is a discussion which followed three presentations at the Evidence Based Perioperaive Medicine (EBPOM) World Congress in London on artificial intelligence in perioperative medicine. Although, for an informed listener, it will work as a standalone piece the presentations which it is in part a response to are here: Part one is here: https://topmedtalk.libsyn.com/ai-in-perioperative-care-part-1-ebpom-london-2023 Part two is here: https://topmedtalk.libsyn.com/artificial-intelligence-in-perioperative-care-part-2-ebpom-2023 Part three is here: https://topmedtalk.libsyn.com/ai-predictive-monitoring-to-prevent-hemodynamic-instability-and-deterioration-in-perioperative-and-acute-care-patients-ebpom-world-congress On the panel are; Feras Hatib, Vice President of the R&D Algorithms and Signal Processing organization for Critical Care and Vascular at Edwards Lifesciences in Irvine California, Adriane Chapman, Professor at University of Southampton, Head of Digital Health Research Group, Director for the Centre for Health Technologies and Sandy (Alexander) Jackson, specialty trainee in anaesthetics and intensive care medicine and a National Institute for Health and Care Research (NIHR) Doctoral Fellow at the University of Southampton. This piece is chaired by TopMedTalk's co-editor in Chief Mike Grocott, Professor of Anaesthesia and Critical Care Medicine at the University of Southampton.

“AI Predictive Monitoring to prevent Hemodynamic Instability and Deterioration in Perioperative and Acute Care Patients” was a talk given at the Evidence Based Perioperative Medicine (EBPOM) World Congress. For more on their conferences check out www.ebpom.org Presented by Feras Hatib, Vice President of the R&D Algorithms and Signal Processing organization for Critical Care and Vascular at Edwards Lifesciences in Irvine California. This piece works as a standalone talk but it is part 3 of a 4 part series. Part one is here: https://topmedtalk.libsyn.com/ai-in-perioperative-care-part-1-ebpom-london-2023 Part two is here: https://topmedtalk.libsyn.com/artificial-intelligence-in-perioperative-care-part-2-ebpom-2023 And, still to come, a fascinating panel discussion. Make sure you like and subscribe to TopMedTalk so you hear it first.

ChatGPT4 in medical writing and editing at learnAMAstyle.com Nascentmc.com for medical writing assistance for your company. Visit nascentmc.com/podcast for full show notes Tricuspid Valve Replacement System for Tricuspid Regurgitation The FDA approved the Evoque tricuspid valve replacement system, a first in the U.S. for a transcatheter tricuspid device, after the TRISCEND II trial showed significant improvements in TR grade and patient symptoms. TR, where the heart's valve does not close properly causing blood backflow, can now be treated with this device, which also received CE Mark approval in Europe and is produced by Edwards Lifesciences. Afami-Cel for Synovial Sarcoma The FDA is prioritizing the review of afamitresgene autoleucel (afami-cel) for advanced synovial sarcoma, based on positive results from the SPEARHEAD-1 trial showing a 39% response rate and increased survival rates. Afami-cel targets MAGE-A4 in synovial sarcoma, a rare soft tissue sarcoma, offering a new treatment option for this aggressive disease. It's manufactured by Adaptimmune Therapeutics with a decision expected by August 4, 2024.  Pulsed Field Ablation for Atrial Fibrillation Boston Scientific's FARAPULSE PFA System has been FDA approved for treating intermittent atrial fibrillation, offering a non-thermal, tissue-selective ablation alternative with proven safety and efficacy. The approval was based on the ADVENT study and real-world data, highlighting shorter ablation times and no severe side effects. Boston Scientific plans an immediate U.S. launch. Shorter Turnaround Time for Axi-cel The FDA approved a manufacturing process change for axi-cel (Yescarta), reducing delivery time from 16 to 14 days, which is a CD19-directed CAR T-cell therapy for certain lymphomas. This change, granted to Kite, a Gilead Sciences subsidiary, aims to improve treatment accessibility by offering faster delivery of this personalized therapy. AI Algorithm for Cervical Cancer Screening Hologic's Genius™ Digital Diagnostics System with the Genius™ Cervical AI algorithm has been FDA approved, introducing the first digital cytology platform integrating AI for cervical cancer screening. This system digitizes traditional Pap test slides, applying AI to enhance detection of pre-cancerous and cancerous cells, improving sensitivity and enabling remote case review. It will be available in the U.S. in early 2024. Trastuzumab Deruxtecan for Solid Tumors The FDA granted priority review to trastuzumab deruxtecan for treating unresectable or metastatic HER2-positive solid tumors, potentially marking it as the first HER2-directed, tumor-agnostic therapy. Based on the DESTINY-PanTumor02 study, showing promising survival outcomes, a decision is expected in the second quarter of 2024. The drug is developed by AstraZeneca and Daiichi Sankyo.  

Jonathan MacWilliams holds a bachelor's degree in metallurgical engineering and has held positions from metallurgist to distinguished engineer at GE to Norman Noble to Mert Medical and now Edwards Lifesciences, where he is currently tasked with developing technical leadership and mentoring programs.Aaron Moncur, hostAbout Being An Engineer The Being An Engineer podcast is a repository for industry knowledge and a tool through which engineers learn about and connect with relevant companies, technologies, people resources, and opportunities. We feature successful mechanical engineers and interview engineers who are passionate about their work and who made a great impact on the engineering community. The Being An Engineer podcast is brought to you by Pipeline Design & Engineering. Pipeline partners with medical & other device engineering teams who need turnkey equipment such as cycle test machines, custom test fixtures, automation equipment, assembly jigs, inspection stations and more. You can find us on the web at www.teampipeline.us

This talk “Advancing POM in New Zealand and Australia” was originally the EBPOM Visiting Professor Plenary Lecture given at the Evidence Based Perioperative Medicine (EBPOM) 2023 World Congress. Our visiting Professor is Vanessa Beavis, the Immediate Past President of The Australian and New Zealand College of Anaesthetists (ANZCA), having just completed her 2 year term, she is a specialist anaesthetist at Auckland City Hospital, New Zealand and also an Honorary Senior Lecturer at the Department of Anaesthesiology, Auckland University. She is introduced by Monty Mythen, Senior Vice President Medical Affairs, Edwards Lifesciences, Critical Care and Emeritus Professor of Anaesthesia and Critical Care, University College London. Find out more about the ANZCA Diploma of Perioperative Medicine here: https://www.anzca.edu.au/education-training/perioperative-medicine-qualification/dip-pom

Kapil Assudani, CISO at Edwards Lifesciences, shares how he was one payment away from getting kicked out of his Masters program, being resilient and resourceful, building credibility, and finding ways to reduce the attack surface.About Kapil: Kapil Assudani, with over 20 years of experience in information security, currently holds the position of Senior Vice President and Chief Information Security Officer at Edwards Lifesciences. His tenure at Edwards, spanning over six years, has responsibilities beyond the typical enterprise security scope of a CISO, as it includes IoT Medical Device Security and Manufacturing Plant security on a global scale.Kapil's leadership philosophy is built on three key principles. Firstly, he believes in building a team of passionate and good-hearted individuals, providing them with innovative tools, and then allowing them to operate independently. Secondly, he emphasizes presenting security problem statements backed by facts and data, simplifying them to a level where a business leader can independently make risk decisions. Lastly, he focuses on building trusted relationships across the entire employee base, fostering candid conversations and driving an execution-focused culture.His extensive experience covers all facets of information security, including leading security incident detection and response, ethical hacking teams, and security architecture and strategy programs. He has also been instrumental in building a global cybersecurity program at Edwards from the ground up. Kapil's diverse industry experience spans consulting and corporate roles across Fortune 100 companies in accounting, finance, healthcare, and technology. Over the last decade, he has intentionally focused his career on healthcare companies, finding the work purposeful and passionately aligned with a noble mission. Kapil holds a Masters in Computer Science and has been a speaker at multiple conferences, further solidifying his expertise in the fieldSPONSER NOTE: Support for Cloud Ace podcast comes from SANS Institute. If you like the topics covered in this podcast and would like to learn more about cloud security, SANS Cloud Security curriculum is here to support your journey into building, deploying, and managing secure cloud infrastructure, platforms, and applications. Whether you are on a technical flight plan, or a leadership one, SANS Cloud Security curriculum has resources, training, and certifications to fit your needs. Focus on where the cloud is going, not where it is today. Your organization is going to need someone with hands-on technical experience and cloud security-specific knowledge. You will be prepared not only for your current role, but also for a cutting-edge future in cloud security. Review and Download Cloud Security Resources: sans.org/cloud-security/ Join our growing and diverse community of cloud security professionals on your platform of choice: Discord | Twitter | LinkedIn | YouTube

Integrating biodesign principles can drive innovative breakthroughs in medical device technology. But what exactly is biodesign, and how can medtech companies utilize it to drive innovation?On this week's Medical Alley Podcast, Greg Johnson of Veranex and Todd Brinton of Edwards Lifesciences join to share more about biodesign and how they've utilized it at their respective organizations. Both have experience the Stanford Byers Center for Design, which was co-founded by former Medical Alley Podcast guest Josh Makower.Tune in to learn more about the concept of biodesign — a structural process for thinking about innovation — and hear Greg and Todd share their visions for the future of biodesign in medtech.Follow Medical Alley on social media on LinkedIn, Facebook, Twitter and Instagram.

Join us in this informative podcast as we sit down with Dr. Engelman and Dr. Grant, esteemed members of the ERAS Cardiac Society. In this engaging interview, they introduce themselves and share insights into their backgrounds. Delving deeper, they discuss their quality improvement programs and how they're revolutionizing patient care. Discover the strategies that have proven most successful in enhancing patient care within the operating room and intensive care unit. The doctors also draw from their extensive experience in implementing Enhanced Surgical Recovery programs, offering valuable insights into the outcomes achieved. To top it off, they share expert advice for clinical leaders on making the most of ERAS, making this podcast a must-listen for anyone in the healthcare field.This episode is sponsored by Edwards Lifesciences.

This engaging conversation gets into how and why trials and research are moving forward. Find out more about the conference we discuss here: https://euroanaesthesia.org Presented by Desiree Chappell and Monty Mythen with their guests Wolfgang Buhre, Professor and Chair, Department of Anesthesiology, Division of Vital Functions, University Medical Center, Utrecht, The Netherlands and Thomas Sheeren, Senior Director Medical Affairs CC EMEACLA, Edwards Lifesciences. -- Originally streamed live as part of our coverage of Anesthesiology 2023; the annual meeting of the American Society of Anesthesiologists (ASA), the largest and most important gathering of anesthesiologists in the world. We're your free front row seat. For more on the ASA go here: https://www.asahq.org/ Check out our YouTube page for a record of the live stream video of this podcast: https://www.youtube.com/@topmedtalk7687/streams

Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here's what you need to know for today, October 24, 2023. Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast. We are back for a new episode of the Fast Five after a week-long hiatus to focus on our DeviceTalks West conference in Santa Clara, California. Before we jump into the news you should know for today, we would be remiss if we didn't talk about the biggest stories from last week – J&J MedTech is restructuring its orthopedics business, and there's finally some insight into what caused the EU antitrust probe into Edwards Lifesciences' business. We break down the news we missed last week and more to get the show started. Plus, you can find all coverage from DeviceTalks West on MassDevice and on our sister site Medical Design & Outsourcing. This week, GE HealthCare announced a cardiac imaging collaboration with Boston Scientific. Fast Five hosts Danielle Kirsh and Sean Whooley discuss the goal of the collaboration and some of the highlights GE HealthCare is expected to showcase at TCT this week in San Francisco. iCad has sold its Xoft brachytherapy business to Elekta. Find out the value of the deal and what technology Elekta is acquiring in this deal, plus executive reactions.  The FDA cleared Insulet's iPhone app for Omnipod 5. The clearance is a long time coming. Hear what makes this clearance significant, what analysts think and some of the challenges that had to be overcome to make the Omnipod 5, according to Chief Technology Officer Mark Field during a DeviceTalks West conversation. Philips posted Q3 earnings results this week that included an increased outlook for the year despite ongoing role reductions and the implications of the Respironics recall. Whooley details the financial highlights of the quarter, what the company attributed the growth to and the updates Philips provided regarding the Respironics recall. Medtronic won an FDA nod for its extravascular defibrillator. Find out what the system is and how it works, and what doctors think about the technology in today's episode.

What is the future of TopMedTalk, where will we find our new Editor in Chief? This podcast has all the answers. Make sure you are subscribed to this podcast so you don't miss a minute of our coverage of the annual meeting of the American Society of Anesthesiologists; Anesthesiology 2023. It's the largest and most important gathering of anesthesiologists in the world and we're your free front row seat. For more on the ASA go here: https://www.asahq.org/ Also, check out our LIVE FREE VIDEO STREAM here: https://www.youtube.com/watch?v=JPpwNqaVXP8 This podcast features Desiree Chappell, our lead US presenter, a Certified Registered Nurse Anesthetist (CRNA) and Vice President of Clinical Quality for NorthStar Anesthesia, Monty Mythen, Senior Vice President Medical Affairs, Edwards Lifesciences, Critical Care, Emeritus Professor of Anaesthesia and Critical Care, University College London, Mike Grocott, Professor of Anaesthesia and Critical Care Medicine at the University of Southampton and an NIHR Senior Investigator and Guy Ludbrook, Professor of Anaesthesia at the University of Adelaide and Royal Adelaide Hospital.

The annual meeting of the American Society of Anesthesiologists; Anesthesiology 2023, it's the largest and most important gathering of anesthesiologists in the world and we're your free front row seat. For more on the ASA go here: https://www.asahq.org/ Make sure you subscribe to TopMedTalk and follow along as all our conversations from the conference make their way to you. In this piece we're getting a feel for the conference on our second day there, featuring Desiree Chappell, our lead US presenter, a Certified Registered Nurse Anesthetist (CRNA) and Vice President of Clinical Quality for NorthStar Anesthesia, Mike Grocott, Professor of Anaesthesia and Critical Care Medicine at the University of Southampton and an NIHR Senior Investigator, Monty Mythen, Senior Vice President Medical Affairs, Edwards Lifesciences, Critical Care, Emeritus Professor of Anaesthesia and Critical Care, University College London, and Guy Ludbrook, Professor of Anaesthesia at the University of Adelaide and Royal Adelaide Hospital.

Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here's what you need to know for today, September 28, 2023. Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast. QT Medical this week announced it raised $12 million in a Series B funding round. Fast Five hosts Sean Whooley and Danielle Kirsh explain what that technology is and how optimistic executives are feeling after the funding round.  BCIs are in the news again this week.  This time, Onward announced the first-in-human implant of a stimulator with BCI technology. Whooley details how the technology works with the BCI and what doctors think after the first implant.  Boston Scientific won an FDA nod for its intravascular ultrasound system. Hear how the system works and how it assists clinicians, as well as some of the features that help support clinicians.  The NIH this week chose Boston as its location for its ARPA-H Catalyst Hub. The Fast Five hosts discuss the details behind this NIH initiative and what organizations will be a part of the hub.  Edwards Lifesciences was revealed as the mystery company facing antitrust scrutiny in Europe, first announced last week. Find out what Edwards' response was to the antitrust investigation.

Value-based care has been dominating industry conversations in recent years. Here on Radio Advisory, we talk a lot about best practices, how to make the right investments, and how to best prepare leaders for the future of value-based care. But given all this momentum, we want to spend time asking the question: what are the misconceptions or misaligned expectations that leaders have around value-based care? In this episode, host Rachel (Rae) Woods invites Advisory Board value-based care expert Daniel Kuzmanovich and Optum Advisory Service's SVP of value-based care, Erik Johnson, to discuss the mindset shifts they think leaders should be making when pursuing a sustainable value-based care strategy. Throughout the conversation they discuss what leaders are currently getting wrong, how myths about value-based care are impacting the industry, and more. Links: Ep. 172: Build a value-based enterprise: Live from 2023 Value-Based Care Summit Ep. 126: [Bonus content] Commercial risk is possible—here's how How Health Plans Can Support Providers in Risk The climb to value-based care [Upcoming Roundtable, Nov. 9-10] Shaping the New Era of Value-Based Care Learn more about Advisory Board's value-based care on-demand courses Explore what volumes and revenues a structural heart program could capture in different scenarios, with Advisory Board's new calculator, sponsored by Edwards Lifesciences. Advisory Board is a subsidiary of Optum. All Advisory Board research, expert perspectives, and recommendations remain independent.

TopMedTalk recorded this piece at the European Society of Anaesthesiology and Intensive Care (ESAIC) conference, Euroanaesthesia 2023 in Glasgow. It features Desiree Chappell, Monty Mythen and Andy Cumpstey in conversation with Vera von Dossow, Director of the Institute for Anesthesiology and Pain Therapy at the HDZ NRW, Bad Oeynhausen. With thanks to Edwards Lifesciences for their generous support in bringing free open access medical education to you.

Danny Pane is a mechanical engineer and senior principal engineer at Edwards Lifesciences. Danny has experience as an engineering expert witness and in process development, and is also an active user of OnShape, a modern cloud-based CAD program we've talked a little about on the podcast before.Aaron Moncur, hostAbout Being An Engineer The Being An Engineer podcast is a repository for industry knowledge and a tool through which engineers learn about and connect with relevant companies, technologies, people resources, and opportunities. We feature successful mechanical engineers and interview engineers who are passionate about their work and who made a great impact on the engineering community. The Being An Engineer podcast is brought to you by Pipeline Design & Engineering. Pipeline partners with medical & other device engineering teams who need turnkey equipment such as cycle test machines, custom test fixtures, automation equipment, assembly jigs, inspection stations and more. You can find us on the web at www.teampipeline.us